Alexander Cumbo
Förmögenhet: 2 M $ per 2026-08-31
Förmögenhet: 2 M $ per 2026-08-31
Mr. Alexander G.
Cumbo is an Independent Director at Vor Biopharma, Inc., an Independent Director at Climb Bio, Inc. and a President, Chief Executive Officer & Director at Solid Biosciences, Inc. He is on the Board of Directors at Vor Biopharma, Inc., Climb Bio, Inc. and Solid Biosciences, Inc. Mr. Cumbo was previously employed as an Independent Director by Verve Therapeutics, Inc., a President, Chief Executive Officer & Director by AavantiBio, Inc., an Independent Director by RA Pharmaceuticals, Inc., a Chief Commercial Officer & Executive VP by Sarepta Therapeutics, Inc., and a Vice President-Sales & Treatment Education by Vertex Pharmaceuticals, Inc. He also served on the board at Clinical Supplies Management, Inc. He received his undergraduate degree from Auburn University.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
SOLID BIOSCIENCES INC. 0,22 % | 2026-03-31 | 235 405 ( 0,22 % ) | 2 M $ | 2026-08-31 |
CLIMB BIO, INC. -.--% | 2026-06-05 | 0 ( -.--% ) | - $ | 2026-08-31 |
VOR BIOPHARMA, INC. -.--% | 2026-06-11 | 0 ( -.--% ) | - $ | 2026-08-31 |
| Företag | Position | Start |
|---|---|---|
| SOLID BIOSCIENCES INC. | Verkställande Direktör | 2022-12-02 |
| CLIMB BIO, INC. | Direktör/Styrelseledamot | 2025-03-28 |
| VOR BIOPHARMA INC. | Direktör/Styrelseledamot | 2025-07-16 |
| Företag | Position | Slut |
|---|---|---|
| VERE THER | Direktör/Styrelseledamot | 2025-07-25 |
Aavantibio, Inc.
Aavantibio, Inc. BiotechnologyHealth Technology Operates as biotechnology company that develops new gene therapies | Verkställande Direktör | 2022-12-01 |
| SAREPTA THERAPEUTICS, INC. | Företagsledare/Principal | 2020-10-01 |
| RA PHARMACEUTICALS, INC. | Direktör/Styrelseledamot | 2020-04-02 |
Clinical Supplies Management, Inc.
Clinical Supplies Management, Inc. Medical/Nursing ServicesHealth Services Offers clinical trial services to biotechnology and pharmaceutical companies | Direktör/Styrelseledamot | 2017-01-01 |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 10 |
|---|---|
Vertex Pharmaceuticals, Inc.
Vertex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops drugs for the treatment of cystic fibrosis | Health Technology |
Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures micro-dystrophin gene therapy | Health Technology |
Ra Pharmaceuticals, Inc.
Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of glomerulonephritis, kidney disease and cardiovascular disease | Health Technology |
Auburn University
Auburn University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Clinical Supplies Management, Inc.
Clinical Supplies Management, Inc. Medical/Nursing ServicesHealth Services Offers clinical trial services to biotechnology and pharmaceutical companies | Health Services |
Solid Biosciences, Inc.
Solid Biosciences, Inc. BiotechnologyHealth Technology Operates as a pharmaceutical company that develops treatments through gene therapy for patients with duchenne disease | Health Technology |
Vor Biopharma, Inc.
Vor Biopharma, Inc. BiotechnologyHealth Technology Engages in developing cell therapies | Health Technology |
Eliem Therapeutics, Inc.
Eliem Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders | Health Technology |
Verve Therapeutics, Inc.
Verve Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicines to treat patients with cardiovascular disease | Health Technology |
Aavantibio, Inc.
Aavantibio, Inc. BiotechnologyHealth Technology Operates as biotechnology company that develops new gene therapies | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån